Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Research|August 25, 1991
Binding of insulin-like growth factors to Tera-2 human embryonal carcinoma cells during differentiationJ F Fleck, G W Sledge, S V Benenati, et al.Steroids|July 1, 1987
Discovery and development of a novel class of nonsteroidal aromatase inhibitorsK S Hirsch, C D Jones, T D Lindstrom, et al.Journal of Cellular Biochemistry|August 1, 1993
Platelet-derived growth factor induces proliferation of hyperplastic human prostatic stromal cellsC J Vlahos, T D Kriauciunas, P E Gleason, et al.Journal of Medicinal Chemistry|January 1, 1990
Estrogen synthetase inhibitors. 2. Comparison of the in vitro aromatase inhibitory activity for a variety of nitrogen heterocycles substituted with diarylmethane or diarylmethanol groupsC D Jones, M A Winter, K S Hirsch, et al.Proceedings of the National Academy of Sciences of the United States of America|June 1, 1993
LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1K S Hirsch, C D Jones, J E Audia, et al.Toxicology and Applied Pharmacology|February 1, 1990
Endocrine effects of a new histamine H2-receptor antagonist, nizatidine (LY139037), in the male ratB L Neubauer, R L Goode, K L Best, et al.The Prostate|January 1, 1993
LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male ratsB L Neubauer, K L Best, T R Blohm, et al.The Journal of Urology|June 1, 1993
Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasiaP E Gleason, J A Jones, J S Regan, et al.The Journal of Clinical Endocrinology and Metabolism|June 1, 1996
LY191704 inhibits type I steroid 5 alpha-reductase in human scalpB L Neubauer, H M Gray, C W Hanke, et al.Pageof 2